



PRESS RELEASE

MEDIUM-LONG TERM LOAN AGREEMENT FOR €70 MILLION SIGNED

Verdellino (BG), 25 February 2022

Fine Foods & Pharmaceuticals N.T.M. S.p.A. ("**Fine Foods**") today signed an unsecured loan agreement with Intesa Sanpaolo S.p.A., as sole arranger and financing bank.

The seven-year loan agreement of up to €70 million will be repaid in February 2029. The loan will be used partly for the reorganisation of current financial debt, replacing short-term financing with medium-long term debt, and to further support Fine Foods growth by acquisitions.

The loan includes a year's pre-amortisation, an Euribor indexed interest rate plus a variable margin.

The loan agreement includes contractual conditions and provisions in line with this type of transaction, including compliance with financial covenants. These will be determined on an annual or half-yearly basis, relating to the NFP/EBITDA and NFP/net equity ratios, EBITDA/Financial Charges, early repayment if there is a change of control or disposals, limitations on the distribution of dividends where the NFP/EBITDA ratio exceeds 2.5x, further disclosure obligations, do's and don'ts typical for this type of loan.

Fine Foods Chairman Marco Eigenmann said: *"I am pleased with this financing transaction which will further support Fine Foods' development and growth. The Intesa Sanpaolo transaction confirms Fine Foods' strong credibility in the banking world and the interest of financial institutions in supporting our Group's development and growth."*

This press release is available on the Fine Foods website www.finefoods.it, in the Investor Relations/Press Releases section.



Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Euronext STAR Milan, is an Italian independent Contract Development & Manufacturing Organisation (CDMO). It develops and manufactures contract products for the pharmaceutical and nutraceutical industries. Fine Foods is also active in the cosmetics, biocides and medical devices industries with its acquisition of Pharmatek-PMC and the most recent Euro Cosmetic acquisition.

Founded in 1984, from a pharmaceutical and nutraceutical synergy, Fine Foods has been pursuing quality and innovation on behalf of its customers as its primary objective. With € 172 million revenue in 2020 and an 11 per cent CAGR over the last decade, it is a growing and future-oriented company.

The sustainability of the business model and the holistic approach to ESG, together with product innovation, are drivers that will allow the company to fully develop its intrinsic potential.

For information:

Fine Foods & Pharmaceuticals N.T.M. S.p.A.

Investor Relations

tel. +39 035 4821382

ir@finefoods.it

CDR Communication

Media Relations

Marianna Tremolada

marianna.tremolada@cdr-communication.it